HOTH: Analysten-Ziel $5 — AI-Analyse (Apr 2026)
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs. Their pipeline includes treatments for skin disorders, cancers, Alzheimer's, inflammatory bowel diseases, asthma, allergies, lung diseases, COVID-19, eczema and lupus.
Unternehmensueberblick
Kurzfassung:
Was macht HOTH?
Was ist die Investmentthese fuer HOTH?
In welcher Branche ist HOTH taetig?
Welche Wachstumschancen hat HOTH?
- BioLexa Platform for Eczema Treatment: The BioLexa Platform, currently in Phase I clinical trials for the treatment of eczema, represents a significant growth opportunity for Hoth Therapeutics. The global eczema market is projected to reach $13.7 billion by 2030, driven by the increasing prevalence of the condition and the demand for more effective treatments. Successful completion of clinical trials and subsequent commercialization of BioLexa could generate substantial revenue for Hoth. Timeline: Phase II trials expected to commence in late 2026.
- HT-001 for Skin Disorders: HT-001, a topical formulation for treating rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy, addresses a significant unmet need in cancer treatment. The market for supportive care products in oncology is growing, driven by the increasing use of targeted therapies. Positive clinical trial results for HT-001 could lead to partnerships with pharmaceutical companies and commercialization of the product. Timeline: Phase II trials expected to commence in mid-2026.
- HT-ALZ for Alzheimer's Disease: Hoth's HT-ALZ program targets Alzheimer's disease, a large and growing market with limited treatment options. The global Alzheimer's disease market is projected to reach $12.6 billion by 2030, driven by the aging population and the increasing prevalence of the disease. Successful development of HT-ALZ could position Hoth as a leader in the Alzheimer's therapeutics market. Timeline: Preclinical studies ongoing, with Phase I trials anticipated in 2027.
- HT-KIT for Mast-Cell Derived Cancers and Anaphylaxis: The development of HT-KIT to treat mast-cell derived cancers and anaphylaxis presents a targeted growth opportunity. The market for anaphylaxis treatment is expanding due to increasing awareness and diagnosis rates. Success in this area could lead to a valuable niche product for Hoth. Timeline: Preclinical studies ongoing, with Phase I trials anticipated in 2027.
- Strategic Partnerships and Licensing Agreements: Hoth's strategy of forming strategic partnerships and licensing agreements with leading universities and biotechnology companies provides access to valuable intellectual property and expertise. These collaborations can accelerate drug development and expand the company's pipeline. Continued pursuit of strategic partnerships will be crucial for Hoth's long-term growth. Ongoing: Actively seeking collaborations to expand pipeline.
- Market capitalization of $0.01 billion indicates a small-cap company with potential for high growth but also higher risk.
- P/E ratio of -0.99 reflects the company's current lack of profitability, typical for clinical-stage biopharmaceutical companies.
- Beta of 0.57 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- Focus on unmet medical needs across a diverse range of therapeutic areas, including dermatology, oncology, and neurology, diversifies risk.
- Strategic collaborations with leading universities and biotechnology companies provide access to valuable intellectual property and expertise.
Welche Produkte und Dienstleistungen bietet HOTH an?
- Develop therapies for skin disorders associated with cancer treatments.
- Develop treatments for mast-cell derived cancers and anaphylaxis.
- Develop therapies for Alzheimer's disease and other neuroinflammatory diseases.
- Develop treatments for inflammatory bowel diseases, acne, and psoriasis.
- Develop treatments for asthma and allergies using inhalational administration.
- Develop treatments for lung diseases resulting from bacterial infections.
- Develop a novel peptide for treating COVID-19.
- Develop treatments for lupus.
Wie verdient HOTH Geld?
- Develops pharmaceutical assets through in-house research and development.
- Out-licenses or partners its assets with larger pharmaceutical companies for further development and commercialization.
- Generates revenue through milestone payments, royalties on sales of licensed products, and potential direct sales of approved products.
- Pharmaceutical companies seeking to license or acquire novel drug candidates.
- Patients suffering from skin disorders, cancers, Alzheimer's disease, and other diseases targeted by Hoth's pipeline.
- Healthcare providers who prescribe Hoth's therapies to their patients.
- Proprietary Drug Compound Platform: The BioLexa Platform is a patented drug compound platform, providing a competitive advantage in the development of new therapies.
- Strategic Partnerships: Collaborations with leading universities and biotechnology companies provide access to valuable intellectual property and expertise.
- Diverse Pipeline: A broad pipeline of therapeutic candidates targeting a range of diseases diversifies risk and provides multiple opportunities for value creation.
Was koennte die HOTH-Aktie steigen lassen?
- Upcoming: Phase II clinical trial results for BioLexa Platform in eczema (expected late 2026).
- Upcoming: Phase II clinical trial results for HT-001 in skin disorders (expected mid-2026).
- Ongoing: Advancement of HT-ALZ program into Phase I clinical trials (anticipated 2027).
- Ongoing: Continued strategic partnerships and licensing agreements to expand pipeline.
- Ongoing: Potential for orphan drug designations for certain therapeutic candidates.
Was sind die wichtigsten Risiken fuer HOTH?
- Potential: Clinical trial failures or delays could significantly impact the company's value.
- Potential: Regulatory hurdles and delays in obtaining marketing approvals.
- Ongoing: Competition from larger pharmaceutical companies and other biotechnology firms.
- Ongoing: Dependence on external funding to support research and development.
- Ongoing: Intellectual property challenges and patent disputes.
Was sind die wichtigsten Staerken von HOTH?
- Diverse pipeline of therapeutic candidates targeting a range of diseases.
- Proprietary drug compound platform (BioLexa).
- Strategic partnerships with leading universities and biotechnology companies.
- Low Beta indicates lower volatility.
Was sind die Schwaechen von HOTH?
- Clinical-stage company with no currently approved products and no revenue.
- Small market capitalization and limited financial resources.
- Reliance on external funding to support research and development.
- Only 2 employees.
Welche Chancen hat HOTH?
- Successful completion of clinical trials and regulatory approvals for lead product candidates.
- Expansion of pipeline through strategic partnerships and acquisitions.
- Growing demand for novel therapies to address unmet medical needs.
- Potential for orphan drug designations and accelerated regulatory pathways.
Welchen Risiken ist HOTH ausgesetzt?
- Clinical trial failures and regulatory setbacks.
- Competition from larger pharmaceutical companies and other biotechnology firms.
- Difficulty in raising capital to fund research and development.
- Intellectual property challenges and patent disputes.
Wer sind die Wettbewerber von HOTH?
- Asensus Surgical, Inc. — Focuses on surgical robotics, different therapeutic area. — (ASBP)
- BriaCell Therapeutics Corp. — Focuses on cancer immunotherapy. — (BCTX)
- Curis, Inc. — Develops cancer therapies. — (CRIS)
- Dare Bioscience, Inc. — Focuses on women's health products. — (DARE)
- Entos Pharmaceuticals Inc. — Develops genetic medicines. — (ENTO)
Key Metrics
- Price: $0.56 (-3.39%)
- Market Cap: $8
- Volume: NaN
- MoonshotScore: 45/100
Analyst Price Target
- Analyst Consensus Target: $5.00
- Current Price: $0.56
- Implied Upside: +793.8%
Company Profile
- CEO: Robb Knie
- Headquarters: New York City, NY, US
- Employees: 2
- Founded: 2019
AI Insight
Fragen & Antworten
What does Hoth Therapeutics, Inc. do?
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs. The company's pipeline includes treatments for a range of diseases, including skin disorders, cancers, Alzheimer's disease, inflammatory bowel diseases, asthma, allergies, lung diseases, and COVID-19. Hoth's business model involves developing pharmaceutical assets through in-house research and development, out-licensing or partnering its assets with larger pharmaceutical companies, and generating revenue through milestone payments, royalties, and potential direct sales of approved products. The company is focused on advancing its clinical programs and delivering innovative solutions to patients in need.
Is HOTH stock a good buy?
HOTH stock represents a high-risk, high-reward investment opportunity. The company's diverse pipeline and strategic partnerships offer significant potential for value creation. However, investors should be aware of the inherent risks associated with clinical-stage biopharmaceutical companies, including regulatory hurdles, clinical trial failures, and the need for additional capital. The company's negative P/E ratio reflects its current lack of profitability. Positive clinical trial results for BioLexa Platform and HT-001 could drive significant stock appreciation, while negative results could lead to a substantial decline. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in HOTH.
What are the main risks for HOTH?
The main risks for Hoth Therapeutics include clinical trial failures, regulatory setbacks, competition from larger pharmaceutical companies, dependence on external funding, and intellectual property challenges. Clinical trial failures could significantly impact the company's value and delay or halt the development of its therapeutic candidates. Regulatory hurdles and delays in obtaining marketing approvals could also negatively affect the company's prospects. Competition from larger pharmaceutical companies with greater resources could limit Hoth's market share. The company's reliance on external funding makes it vulnerable to market conditions and investor sentiment. Intellectual property challenges and patent disputes could threaten the company's competitive advantage.
Is HOTH a good investment right now?
Use the AI score and analyst targets on this page to evaluate Hoth Therapeutics, Inc. (HOTH). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.
What is the MoonshotScore for HOTH?
The MoonshotScore is a proprietary 0-100 AI rating that evaluates Hoth Therapeutics, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.
Where can I find HOTH financial statements?
Hoth Therapeutics, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.
What do analysts say about HOTH?
Analyst consensus targets and ratings for Hoth Therapeutics, Inc. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.
How volatile is HOTH stock?
Check the beta and historical price range on this page to assess Hoth Therapeutics, Inc.'s volatility relative to the broader market.